Tango Therapeutics, Inc.
TNGXNext catalyst
TNG456
Non Small Cell Lung Cancer
Get an email about TNGX's next catalysts
Track Tango Therapeutics (TNGX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 1 past
TNG456 Phase 2 Est. Readout
Primary completion for TNG456 trial (NCT06810544) in Non Small Cell Lung Cancer
SourceTNG462 Phase 2 Est. Readout
Estimated primary completion for TNG462 trial (NCT05732831) in Locally Advanced Solid Tumor. Topline data typically follows completion by weeks to months.
SourceHow TNGX's past catalysts played out
Market Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Tango Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Tango Therapeutics, Inc.'s (TNGX) pipeline across Phase 2. Its lead program is TNG456 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tango Therapeutics, Inc.'s next FDA catalyst?→
Tango Therapeutics, Inc.'s (TNGX) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TNGX biotech catalysts?→
Add TNGX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tango Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.